Viatris Connect

Viatris Connect is an online platform for healthcare professionals. Across the website you will find news, blogs, product information and peer webinars sharing knowledge and experience.

All of our patient support information is easily available to order and download at any time.

REGISTER NOW

Resources

Mylan Connects Logo

You may find the following previews of materials on Dymista® and allergic rhinitis useful. These materials and more can be ordered from the Viatris Connect website.

For HCPs to use:
Guidelines REPRINT MGP

Guidelines REPRINT MGP

Rhinitis management guidelines - includes BSACI guidelines for the diagnosis and management of allergic and non-allergic rhinitis

Lipworth Primary & Secondary Care leave piece

Lipworth Primary & Secondary Care leave piece

Scottish consensus study algorithm’s for allergic rhinitis treatment

A Next Step for Nasal Control

A Next Step for Nasal Control

Double-sided leave piece with key highlights and BSACI algorithm

References

  • Scadding GK, et al. BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis (Revised Edition 2017; First edition 2007). Clin Exp Allergy 2017; 47(7): 856‑889.
  • Scottish Medicine Consortium (SMC). Available at: https://www.scottishmedicines.org.uk/medicines-advice/azelastine-hydrochloride-plusfluticasone- propionate-dymista-abbreviatedsubmission-92113/. Last accessed: May 2022.

The website you are trying to access is designed for healthcare professionals in the UK, the content is not designed for the general public.

Are you a UK healthcare professional?

YES
NO

Viatris Connect is an online platform for UK health Professionals.

Across the website you will find news, blogs and product information.

Register to Viatris Connect today

Please note that the website contains promotional and non-promotional material including educational content and resources to help you and your patients.

REGISTER NOW

Please continue to report suspected adverse drug reactions and device failures with any medicine or vaccine to the MHRA through the Yellow Card Scheme.

It is easiest and quickest to report adverse drug reactions and device failures online via the Yellow Card website: https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. Alternatively, you can report via some clinical IT systems (EMIS/SystmOne/Vision/MiDatabank) or by calling the Commission on Human Medicines (CHM) free phone line: 0800-731-6789.
Adverse reactions/events and device failures should also be reported to MAH at e-mail address: pv.uk@viatris.com.

This website is owned and managed by Viatris. For more information visit viatris.co.uk


This site is intended for UK healthcare professionals only. If you're a patient who has been prescribed Dymista® (azelastine hydrochloride/fluticasone propionate), please ​click here.

Dymista® is indicated for the relief of symptoms of moderate to severe seasonal and perennial allergic rhinitis if monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.​

Copyright © 2023 Viatris Inc All rights reserved. Dymista® is a registered trademark of Viatris Inc.

Viatris UK Healthcare Limited (company registration number 09189103), an English company with a registered office address at 20 Station Close, Potters Bar, Hertfordshire, EN6 1TL (VAT - 421 623 781)

Mylan Logo